Related references
Note: Only part of the references are listed.Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Natalie Mazur et al.
LANCET INFECTIOUS DISEASES (2023)
T follicular helper cells and their impact on humoral responses during pathogen and vaccine challenge
Jennifer A. Juno et al.
CURRENT OPINION IN IMMUNOLOGY (2022)
Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine
Ann R. Falsey et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants
Karoliina Koivisto et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
Laura L. Hammitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine
Emily Phung et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of Life
Andrea G. Buchwald et al.
CLINICAL INFECTIOUS DISEASES (2021)
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses
Maryam Mukhamedova et al.
IMMUNITY (2021)
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
Tracy J. Ruckwardt et al.
LANCET RESPIRATORY MEDICINE (2021)
Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection
Sara A. Taleb et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants
S. A. Madhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
M. Pamela Griffin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults
Adriana Weinberg et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study
Geert Leroux-Roels et al.
VACCINE (2019)
Transient opening of trimeric prefusion RSV F proteins
Morgan S. A. Gilman et al.
NATURE COMMUNICATIONS (2019)
A proof of concept for structure-based vaccine design targeting RSV in humans
Michelle C. Crank et al.
SCIENCE (2019)
Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination
Anna-Karin E. Palm et al.
FRONTIERS IN IMMUNOLOGY (2019)
Immunological Lessons from Respiratory Syncytial Virus Vaccine Development
Tracy J. Ruckwardt et al.
IMMUNITY (2019)
Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention
Anna Aiello et al.
FRONTIERS IN IMMUNOLOGY (2019)
A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein
Aimin Tang et al.
NATURE COMMUNICATIONS (2019)
Epitope-Specific Serological Assays for RSV: Conformation Matters
Emily Phung et al.
VACCINES (2019)
Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation
Eileen Goodwin et al.
IMMUNITY (2018)
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
Natalie I. Mazur et al.
LANCET INFECTIOUS DISEASES (2018)
ICTV Virus Taxonomy Profile: Pneumoviridae
Bert Rima et al.
JOURNAL OF GENERAL VIROLOGY (2017)
Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection
Cristina Capella et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults
Judith Falloon et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate
Bo Liang et al.
JOURNAL OF VIROLOGY (2017)
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
Ting Shi et al.
LANCET (2017)
A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein
Jarrod J. Mousa et al.
NATURE MICROBIOLOGY (2017)
Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus
Mallika Sastry et al.
PLOS ONE (2017)
Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation
Denise Lau et al.
SCIENCE IMMUNOLOGY (2017)
Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses
Judith Falloon et al.
CLINICAL AND VACCINE IMMUNOLOGY (2017)
Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination
Ali H. Ellebedy et al.
NATURE IMMUNOLOGY (2016)
Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV
M. Gordon Joyce et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein
Jarrod J. Mousa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant
Judith Falloon et al.
VACCINE (2016)
Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV
M. Gordon Joyce et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus
Jeffrey C. Boyington et al.
PLOS ONE (2016)
Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors
Morgan S. A. Gilman et al.
SCIENCE IMMUNOLOGY (2016)
Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate
Bo Liang et al.
JOURNAL OF VIROLOGY (2015)
A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus
Guillaume B. E. Stewart-Jones et al.
PLOS ONE (2015)
Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera
Joan O. Ngwuta et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques
Kathryn Patton et al.
VACCINE (2015)
A Novel Respiratory Syncytial Virus (RSV) F Subunit Vaccine Adjuvanted with GLA-SE Elicits Robust Protective TH1-Type Humoral and Cellular Immunity In Rodent Models
Stacie L. Lambert et al.
PLOS ONE (2015)
Risk Factors for Respiratory Syncytial Virus Illness Among Patients with Chronic Obstructive Pulmonary Disease
Jyotsna Mehta et al.
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2013)
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
Jason S. McLellan et al.
SCIENCE (2013)
Risk factors for severe respiratory syncytial virus infection in elderly persons
EE Walsh et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Share Paper
